In the Press

Saint Herblain (France), July 7, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the U.S

Most interventions were significant and associated with improved efficacy.

Is administration of IL-6 antagonists associated with 28-day all-cause mortality in patients hospitalized for COVID-19?

A large body of evidence shows the harmful effects of cigarette smoke to oral and systemic health.

Fewer antibiotic prescriptions were prescribed for respiratory symptoms during the pandemic than in the comparable pre-pandemic period, in a study of ambulatory clinic patients of the University of Wisconsin Health system in southern Wisconsin.

Spread of the Delta variant blamed for significant rise in cases that have threatened to overwhelm the medical system

A growing share of infections among unvaccinated youths in countries with high vaccination rates is putting the spotlight on the role of young people in the pandemic.

Ventilation systems can be supplemented with portable high efficiency particulate air (HEPA) cleaners to reduce the number of airborne infectious particles.

Infective endocarditis (IE) is a known but uncommon cause of cardioembolic stroke and there are rare but recognized cases of IE without an inflammatory response.

Nanomaterials found in consumer and health-care products can pass from the bloodstream to the brain side of a blood-brain barrier model with varying ease depending on their shape—creating potential neurological impacts that could be both positive and negative, a new study reveals.